Biotech Startups

Huahui Health is a biotech company developing a pipeline of drug candidates targeting major liver diseases, with research rooted in the hepatitis B virus (HBV) infection mechanism. Its work builds on the discovery of the NTCP receptor involved in HBV infection.

1 investor

Capital Biotech (博奥晶典) operates a high-throughput biotechnology service platform in China, developing molecular diagnostics products including prenatal screening and diagnostic tests for birth defect prevention. It also provides genetic testing and forensic DNA identification services for public-health and government programs.

1 investor

Shanghai Jizhi Biochemical is a reagent company specializing in the research and development of biochemical reagents and life science products. The company serves laboratory professionals and scientific research institutions.

1 investor

HerAnova develops non-invasive, blood-based diagnostics and treatments for endometriosis and infertility, aimed at improving women's health. It is building a suite of tests, including a blood-based test for detecting and confirming endometriosis.

1 investor

The company works with recombinant adeno-associated virus (rAAV) vectors, which are engineered from non-pathogenic wild-type AAV, for use in gene research and gene therapy applications.

1 investor

Hubei Topgene Biotechnology is a CRO founded in 2009 that specializes in large-animal studies and focuses on preclinical drug research and evaluation, offering nonclinical safety, pharmacodynamics, pharmacokinetics, bioanalysis, molecular imaging, medical device evaluation, and non-human primate breeding services. It serves innovative drug developers with GLP laboratories meeting Chinese NMPA, US FDA, EU OECD, and Australian TGA standards.

1 investor

A biopharmaceutical company that develops antibody-based drugs using its own integrated antibody technology platforms, with a pipeline spanning a marketed product and multiple clinical and preclinical candidates. Its therapeutic approaches focus on activating NK cells, redirecting T cells, and modulating other immune cells for conditions such as neuromyelitis optica spectrum disorder (NMOSD) and primary membranous nephropathy (pMN) in China.

1 investor

TG ImmunoPharma is a biotech company focused on NK (natural killer) cell-based therapeutics.

1 investor

Taimei provides an online training platform for the pharmaceutical industry, supporting course deployment, test banks, exams, and certification management. It emphasizes regulatory compliance, including ISO certification and Title 21 CFR Part 11 electronic signature standards, with reporting and audit-ready training records.

1 investor

A research-driven specialty pharmaceutical company that develops and commercializes innovative medicines through the 505(b)(2) regulatory pathway, focusing on central nervous system disorders, metabolic diseases, and orphan indications. The company operates in New Jersey and Shanghai, leveraging established molecules with proven safety profiles.

1 investor

Miyatani Natural Science Laboratory isolates and cultures probiotics such as yeast (for sake, beer, and wine), plant-based lactic acid bacteria, and filamentous fungi, providing them on request extracted from customer-specified media like plants or soil. The company, based in Japan, focuses on fermentation research to create new flavors, aromas, and functional microorganisms.

1 investor

Hangzhou Sumgen Biotech is a biopharmaceutical company that develops innovative antibody drugs, including monoclonal antibodies and antibody-drug conjugates (ADCs), for the treatment of cancer and other diseases. Its lead product, enlonstobart (Enshuxing®), received marketing approval from China's NMPA.

1 investor

A Chinese biotech company that uses proprietary synthetic biology to design, develop, and produce bioactive ingredients such as recombinant collagen and rare ginsenosides. Its output targets three areas: functional skincare products, medical devices, and functional/medical-purpose foods.

1 investor

Pharmaron provides drug research and development services globally, supporting the discovery and development of pharmaceutical therapies through integrated capabilities across multiple geographic regions.

1 investor

Kousai (恒赛生物), founded in 2018, is a Chinese biotech company developing and commercializing therapeutic dendritic cell (DC) vaccines for conditions such as relapsed/refractory tumors, chronic viral infections, and autoimmune diseases. It operates the Eco-DCVax platform and its lead pipeline candidate targets EBV-associated hematological and solid tumors.

1 investor

Atom Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for chronic gout, acute gout, and hyperuricemia. Its lead candidate ABP-671 is in multicenter Phase 2b/3 trials worldwide, including the US.

1 investor

Singleron Biotechnologies develops single-cell sequencing technology and applies AI to support the development of next-generation medicines. It works with research institutions and partners in the biomedical field, including as a technology partner for UK and European clinical and academic initiatives.

1 investor

Jingze (Jingze Biopharmaceutical) is a Chinese biopharmaceutical company developing drug candidates focused on assisted reproduction and ophthalmology. Its pipeline includes eight candidate drugs, three of which are in late-stage development.

1 investor

Crystalo Bio provides structural biology and drug discovery services focused on membrane proteins such as GPCRs, ion channels, and transporters, using crystallography, cryo-EM, and NMR. It also offers end-to-end antibody development services (antigen preparation, humanization, nanobodies, bispecific nanobodies) and computational molecular modeling and simulation for pharmaceutical research.

1 investor

aceRNA Technologies develops therapies based on RNA technology, focusing on the discovery of new functions of miRNA to contribute to regenerative medicine and the creation of new drugs for diseases that currently lack treatments. The company operates in the biotech and drug discovery field.

1 investor

AGRI SMILE develops and sells biostimulants made from local food waste and runs a digital platform for agriculture, working with local producers to support sustainable, low-carbon farming. The company researches biostimulant materials and operates Eco-LAB, a council focused on evaluating and applying biostimulant technology for regional agricultural challenges.

1 investor

Arktus Therapeutics develops regenerative medicine treatments derived from iPS cells, initially focusing on knee joint diseases with plans to expand to additional organ systems. The company brings together clinical, research, and regulatory expertise to advance innovative cell-based therapeutic products.

1 investor

Forema is a Japanese company working on gut microbiome analysis and lactic acid bacteria strains, including a beta microbiome analysis service for children with autism and proprietary bacterial strains. It also operates retail and other product initiatives related to these offerings.

1 investor

HikariQ Health develops innovative immunoassay methods and antibody therapeutics using proprietary Q-body technology, a fluorescence quenching-based antibody modification technique. The company targets pharmaceutical and medical applications to improve healthcare diagnostics and therapeutics globally.

1 investor